-+ 0.00%
-+ 0.00%
-+ 0.00%

SYS6062, a holding subsidiary of CSPC Pharmaceutical Innovation (300765.SZ), starts phase I/II clinical trials

Zhitongcaijing·11/05/2026 08:57:09
Listen to the news

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biotech”), the holding subsidiary of the company, has recently initiated phase I/II clinical trials to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and efficacy of SYS6062 in patients with advanced solid tumors.

SYS6062 is an antibody conjugation drug (ADC) developed by Dushi Biotech that targets cancer embryonic antigen-related cell adhesion molecule 5 (CEACAM5). The antibody part can specifically bind to the surface of tumor cells expressing CEACAM5 and internalize it into the cell. After specific cleavage by protease, small molecules of toxins are released, thereby killing tumor cells, and can exert a bystander effect to kill surrounding tumor tissue cells without specificity.